Today: 27 June 2026
Oracle stock snaps back after OpenAI upgrade call — $50 billion fundraising looms

Oracle stock snaps back after OpenAI upgrade call — $50 billion fundraising looms

New York, Feb 10, 2026, 05:05 EST — Premarket

Oracle rallied 9.7% to finish Monday at $156.59, buoyed by a D.A. Davidson upgrade to “buy.” The firm said concerns tied to Oracle’s OpenAI exposure were fading. That puts Oracle in the spotlight again when U.S. markets reopen Tuesday. TipRanks

The timing is key here, as Oracle looks to rally the cash it needs for a rapid Oracle Cloud Infrastructure buildout, all while keeping investors comfortable about both dilution and leverage. On Feb. 1, the company laid out its plan to raise $45 billion to $50 billion in gross proceeds during calendar 2026. That haul will come from a mix of debt and equity, Oracle said, including up to $20 billion through an at-the-market program—basically, a way to drip shares into the market at current prices.

The pressure is clear in big tech, with AI investments pushing companies to tap debt markets. Alphabet just priced a $20 billion bond issue on Monday, coming after Oracle’s $25 billion bond sale earlier in the month, Reuters reported. “AI has eaten in to cash flows of software companies,” CredCore co-founder Karthik Nandyal told the outlet. Reuters

Oracle’s pricing term sheet, filed Feb. 2, detailed an investment-grade notes sale spanning several maturities—among them, floating-rate paper maturing in 2029 and fixed-rate bonds stretching all the way to 2066. Unlike speculative-grade issuers, companies with higher credit ratings typically tap the market with investment-grade debt, which usually comes priced over government benchmarks by a set spread.

Gil Luria at D.A. Davidson thinks the market reaction went too far, telling clients a “revamped OpenAI” backed by new capital should have no trouble paying Oracle. He pointed out OpenAI “already has as much as $40B of cash on hand” with the possibility of raising another $100B. Right now, he said, “The market is currently assigning the OpenAI relationship a negative value.” Investing.com

The relief rally isn’t convincing everyone. On Monday, Melius Research cut Oracle to “hold” from “buy,” sticking with a $160 target. The firm knocked Oracle for not generating cash and flagged growing AI competition. Melius cautioned there’s “no guarantee that OpenAI beats Anthropic and Google.” Investing.com

OpenAI’s tie-up with Oracle has been a major force behind the stock’s recent volatility. Last year, Reuters flagged a Wall Street Journal story that said OpenAI agreed to buy $300 billion worth of computing power from Oracle over about five years. The market’s been wrestling with how fast deals like that turn into actual revenue—and what Oracle might have to spend before seeing any returns.

Traders are zeroed in on mechanics now: how fast Oracle draws on the equity program, how much debt the market can handle, and if big customers stick with their build timelines. News about OpenAI funding or capacity could jolt the stock in a hurry.

Action across the AI supply chain remains choppy. Microsoft climbed 3.1%, Nvidia tacked on 2.4% last session. Both moves highlight just how fast sentiment can flip as investors try to figure out the winners—and who’s left footing the bill—in the scramble to scale up.

Still, the risks are clear enough. Higher financing costs or delayed deployments from major customers could leave Oracle shelling out cash before revenue catches up, all while shareholders take on more dilution—never a great mix, even for “strategic” capex plays.

Oracle’s upcoming earnings, due around March 9, are the next obvious trigger. Investors want specifics: cloud demand, capex, and how quickly funding is flowing.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Telix Pharmaceuticals and Two Australian Insider-Led Growth Stocks Highlighted
    June 27, 2026, 11:07 AM EDT. Telix Pharmaceuticals (ASX:TLX), a A$5.2 billion biopharmaceutical firm specializing in radiopharmaceuticals for cancer imaging and treatment, draws growth-focused investors despite ongoing losses. The company reported US$621.9 million revenue from Precision Medicine and relies heavily on its oncology pipeline with products like Illuccix and late-stage candidates TLX591 and TLX101. Key risks include high R&D costs, regulatory scrutiny, pricing pressures, and trial dependencies. Also featured are two Australian insider-led growth stocks identified by the Fast Growing Stocks With High Insider Ownership screener, highlighting firms with aligned management-shareholder interests amid mixed inflation and cautious central bank policies.

Latest articles

Generate Biomedicines stock ends week back above IPO price as volume jumps

Generate Biomedicines stock ends week back above IPO price as volume jumps

27 June 2026
Generate Biomedicines (NASDAQ:GENB) surged 13.7% since June 18 to close Friday at $16.47—above its $16 IPO price—with heavy volume and a $2.11B market cap, as investors weigh its $516.6M cash pile, ongoing clinical trial risks, and lack of product revenue, while sector momentum lifts biotech stocks.
Snowflake (NYSE:SNOW) finishes up for the week after Russell rebalance trading

Snowflake (NYSE:SNOW) finishes up for the week after Russell rebalance trading

27 June 2026
Snowflake Inc (NYSE:SNOW) surged 9.65% to $248.96 on Friday with trading volume five times the weekly average, driven by FTSE Russell’s U.S. index reconstitution, turning a negative week into a 7.2% gain since June 18, as investors await whether the stock can hold above its previous $225.95–$230.41 range when index-driven liquidity fades next week.
GameStop (NYSE:GME) holds close to cash levels after company guides for $600 million in EBITDA

GameStop (NYSE:GME) holds close to cash levels after company guides for $600 million in EBITDA

27 June 2026
GameStop surged 3.57% to $21.76 and jumped after hours as it forecast FY2026 adjusted EBITDA above $600 million, nearly doubling from 2025; with a $9.76 billion market cap now close to its $9.7 billion in cash, securities, digital assets, and collateral, investors are weighing whether GameStop’s cash-rich balance sheet can support equity while Ryan Cohen pursues an eBay bid.
ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume

ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume

27 June 2026
ImmunityBio surged 11.8% to $8.71 on Friday with volume tripling its average, as Russell index reconstitution took effect; Monday’s trading will reveal if demand persists or if the spike was driven by index flows, with no imminent company events and recent insider selling accounting for just 0.06% of Friday’s volume.
US Economic Calendar Today: Stock Futures Hold Steady as Traders Eye Fed Speeches, Treasury Buyback and Delayed Jobs Data
Previous Story

US Economic Calendar Today: Stock Futures Hold Steady as Traders Eye Fed Speeches, Treasury Buyback and Delayed Jobs Data

Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe
Next Story

Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe

Go toTop